Kyla Hildebrand

Dr. Kyla Hildebrand is a Canadian allergist and clinical immunologist based in Vancouver, British Columbia. She is notable in the COVID-19 pandemic for her role in approving COVID-19 vaccines on the National Advisory Committee on Immunization (NACI).

Hildebrand completed medical school at the University of Manitoba in 2005, Pediatrics Residency at the University of Alberta, and a fellowship in Clinical Immunology and Allergy at the University of Toronto.^{1) 2)} She completed a Master of Science in Community Health at the University of Toronto and was the 2010 recipient of the Royal College of Physicians and Surgeons of Canada Fellowship for Studies in Medical Education.

Hildebrand began her academic career at the University of Western Ontario.

Hildebrand is a researcher at the BC Children's Hospital Research Institute.³⁾ She is also a clinical associate professor in the Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, at the University of British Columbia.⁴⁾

Hildebrand sits on the board of directors for the Canadian Society of Allergy and Clinical Immunology (CSACI), and has received honoraria from the BC Society of Allergy and Immunology (BCSAI).^{5) 6)}

Hildebrand has received funding from AstraZeneca, Boehringer Ingelheim, CSL Behring, MEDA Pharmaceuticals, Merck, Pfizer, Shire Pharma, Stallergenes Greer, Takeda, Teva, Aralez and Pediapharm as recently as 2018.^{7) 8)} She has also received speakers fees from Novartis, and paid travel expenses for AllerGen.⁹⁾

She has also served as a consultant for Food Allergy Canada, and has received honoraria from Health Canada. She received a research grant from the Canadian Allergy, Asthma, and Immunology Foundation.¹⁰⁾

Food Allergy Canada is partnered with Pfizer.¹¹⁾

She has received further funding from Genome British Columbia and the BC Children's Hospital Foundation.^{12) 13)} She has published NACI papers with funding from the Public Health Agency of Canada.¹⁴⁾